NCT04270201 (ALDH2020) is a clinical trial of Saliva collection in Oral Squamous Cell Carcinoma (OSCC), sponsored by Instituto do Cancer do Estado de São Paulo.

Who is sponsoring NCT04270201?

NCT04270201 is sponsored by Instituto do Cancer do Estado de São Paulo.

What drugs are being tested in NCT04270201?

Interventions in NCT04270201: Saliva collection.

What condition does NCT04270201 study?

NCT04270201 studies Oral Squamous Cell Carcinoma (OSCC).

Is NCT04270201 still recruiting?

NCT04270201 is currently status unknown. Last updated 19 May 2021.

Last reviewed 2021-05-19 · How we verify

NCT04270201: ALDH2020

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Determination of ALDH1b1 and ALDH2 Polymorphisms Frequency in the Brazilian Population

Status unknown Last updated 19 May 2021

What this trial tests

trial testing Saliva collection in Oral Squamous Cell Carcinoma (OSCC) in 300 participants. Status unknown.

Timeline

2 January 2022

Primary endpoint
1 December 2022

1 December 2023

Quick facts

Lead sponsor	Instituto do Cancer do Estado de São Paulo
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	300
Start date	2 January 2022
Primary completion	1 December 2022
Estimated completion	1 December 2023
Sites	1 location across Brazil

Drugs / interventions tested

Saliva collection — full drug profile →

Conditions studied

Oral Squamous Cell Carcinoma (OSCC) — all drugs for Oral Squamous Cell Carcinoma (OSCC) →

Sponsor

Instituto do Cancer do Estado de São Paulo — full company profile →

Who can join

18 and older, any sex, with Oral Squamous Cell Carcinoma (OSCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A case-control study with oral squamous cell carcinoma (OSCC) patients from Instituto do Câncer do Estado de São Paulo (ICESP) and healthy volunteers. In this study, it will be collected saliva samples from both groups that will be submitted to sequencing analysis to evaluate the frequency of ALDH1b1 and ALDH2 polymorphisms in the Brazilian population. Also, correlate OSCC risk to alcohol consumption or smoke, by applied questionnaires.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets.
Xia J, Li S, Liu S, Zhang L. · · 2023 · cited 51× · PMID 36694633 · DOI 10.1002/mco2.195
ALDEFLUOR activity, ALDH isoforms, and their clinical significance in cancers.
Duan JJ, Cai J, Gao L, Yu SC. · · 2023 · cited 21× · PMID 36651035 · DOI 10.1080/14756366.2023.2166035

Verify or expand the search:

Other trials of Saliva collection

Trials testing the same drug.

NCT06473506 — Group A Streptococcus Saliva Study · NA · active not recruiting
NCT06183385 — Detection of Saliva by Immunoaffinity and Mass Spectrometry · NA · unknown
NCT04613375 — PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older · completed
NCT06990919 — Evaluation of the Stress Levels of Children and Their Parents · NA · completed
NCT06701214 — The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository · recruiting

Other recruiting trials for Oral Squamous Cell Carcinoma (OSCC)

Currently open trials in the same condition.

NCT07371611 — Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma · Phase 3 · recruiting
NCT07133958 — A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPS · recruiting

Other Instituto do Cancer do Estado de São Paulo trials

Trials by the same sponsor.

NCT06887621 — Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk f · Phase 2 · recruiting
NCT07066046 — Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions · NA · recruiting
NCT06282354 — Telemedicine for Postoperative Follow-up After Oncological Surgeries · unknown
NCT05622136 — Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma · Phase 2 · active not recruiting
NCT05996367 — Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04270201 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto do Cancer do Estado de São Paulo
Last refreshed: 19 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04270201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing